secwatch / observer
8-K filed August 16, 2024, 7:59 PM ET ticker SER CIK 0001708599
leadership confidence high sentiment neutral materiality 0.60

Serina Therapeutics appoints Gregory S. Curhan as CFO, replaces departing interim CFO Andrea Park

Serina Therapeutics, Inc.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Gregory S. Curhan

Chief Financial Officer
SER · Serina Therapeutics, Inc.
Effective
2024-08-16
Filed
August 16, 2024, 7:59 PM ET
On August 15, 2024, the Board of Directors (the “Board”) of Serina Therapeutics, Inc. (the “Company”) appointed Gregory S. Curhan as the Company’s Chief Financial Officer in a non-employee consultant role, effective August 16, 2024.
Departed

Andrea Park

Interim Chief Financial Officer and Chief Accounting Officer
SER · Serina Therapeutics, Inc.
Effective
2024-08-15
Successor
Gregory S. Curhan
Filed
August 16, 2024, 7:59 PM ET
On August 12, 2024, the Company informed Andrea Park, the Company’s Interim Chief Financial Officer and Chief Accounting Officer, that her employment with the Company will end effective August 15, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Gregory S. Curhan was appointed as Chief Financial Officer at Serina Therapeutics, Inc..

Action
appointed
Role
Chief Financial Officer
Exact text from the filing
On August 15, 2024, the Board of Directors (the “Board”) of Serina Therapeutics, Inc. (the “Company”) appointed Gregory S. Curhan as the Company’s Chief Financial Officer in a non-employee consultant role, effective August 16, 2024.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 1.0

Andrea Park departed as Interim Chief Financial Officer and Chief Accounting Officer at Serina Therapeutics, Inc..

Action
informed that employment will end
Role
Interim Chief Financial Officer and Chief Accounting Officer
Exact text from the filing
On August 12, 2024, the Company informed Andrea Park, the Company’s Interim Chief Financial Officer and Chief Accounting Officer, that her employment with the Company will end effective August 15, 2024.
View on SEC.gov

Serina Therapeutics, Inc. filing history →

Source: SEC EDGAR
accession 0001493152-24-032700
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.